Ratings Bodal Chemicals Limited NSE India S.E.

Equities

BODALCHEM

INE338D01028

Market Closed - NSE India S.E. 07:40:29 2024-05-21 EDT 5-day change 1st Jan Change
73.3 INR -1.08% Intraday chart for Bodal Chemicals Limited +1.73% -11.37%

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The opinion of analysts covering the stock has improved over the past four months.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company does not generate enough profits, which is an alarming weak point.
  • With an expected P/E ratio at 122.1 and 19.8 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Specialty Chemicals

1st Jan change Capi. Investor Rating ESG Refinitiv
-11.37% 111M -
+18.52% 67.02B
A-
+3.18% 49.69B
A-
+20.44% 42.41B
B+
+23.39% 26.65B
A-
+12.41% 19.62B
C+
+0.10% 17.1B
B+
+4.18% 15.64B
B+
-26.74% 15.43B
A-
-11.77% 15.3B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW